This is a news story, published by ScienceAlert, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from ScienceAlert, you can click here:
more news from ScienceAlertOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
popular weight loss drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest similar weight loss drugs news, related diabetes drug Mounjaro news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weekly tirzepatide injectionsScienceAlert
•
85% Informative
Tirzepatide, the active ingredient in the popular weight loss drug Zepbound , has been shown to reduce the risk of developing type 2 diabetes in obese or overweight adults with pre-diabetes by a huge 94 percent .
Participants on the 15 mg per week dose lost an average of 22.9 percent of their body weight across the course of the research period.
VR Score
84
Informative language
83
Neutral language
51
Article tone
semi-formal
Language
English
Language complexity
59
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
17
Source diversity
7
Affiliate links
no affiliate links